Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9682981 | 0.79 | NPSR1 (0.45) | NPSR1ERCC1FEN1ERCC4KDM4E | |
| SCHEMBL6382584 | 0.79 | NPSR1 (0.45) | NPSR1ERCC1FEN1ERCC4KDM4E | |
| Favipiravir SCHEMBL6378032 | 0.77 | ERCC1 (0.32) | ERCC1FEN1ERCC4 | |
| SCHEMBL6380750 | 0.76 | NPSR1 (0.41) | NPSR1ERCC1FEN1ERCC4KDM4E | |
| SCHEMBL19207970 | 0.71 | NPSR1 (0.46) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL15093907 | 0.69 | NPSR1 (0.50) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL22139856 | 0.69 | HPGD (0.46) | NPSR1ERCC1FEN1ERCC4KDM4E | |
| SCHEMBL1946585 | 0.68 | KDM4E (0.50) | NPSR1ERCC1FEN1ERCC4KDM4E | |
| SCHEMBL6376308 | 0.68 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL16631730 | 0.68 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100390153-C | Intermediate for producing novel pyrazine derivatives | TOYAMA CHEMICAL CO LTD (JP) | 2008-05-28 | — | — | CN | disclosed |
| CN-1781911-A | Intermediate for producing novel pyrazine derivatives | TOYAMA CHEMICAL CO LTD (JP) | 2006-06-07 | — | — | CN | disclosed |
| CN-1239511-C | Novel pyrazine derivative or salt thereof, and pharmaceutical composition containing the same | TOYAMA CHEMICAL CO LTD (JP) | 2006-02-01 | — | — | CN | disclosed |
| EP-1295890-B1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1256588-B1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO LTD (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-6800629-B2 | VIRICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| CN-1418220-A | Novel pyrazine derivative or salt thereof, pharmaceutical composition containing same, and intermediate for producing both | TOYAMA CHEMICAL CO LTD (JP) | 2003-05-14 | — | — | CN | disclosed |
| EP-1295890-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1256588-A1 | NOVEL PYRAZINE DERIVATIVES OR SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES OR THE SALTS AND INTERMEDIATES FOR THE PREPARATION OF BOTH | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130213-A1 | Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof | GTF3C5, EIF2AK2, GTF3C2 | NPSR1 3303/4885ERCC1 4799/4885FEN1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.